Multiple Myeloma

Introduction

A diagnosis of multiple myeloma raises many questions at once. What is happening inside the bone marrow? How serious is it? What will treatment look like, and for how long? If you or someone close to you has recently been diagnosed, or is moving into the next phase of treatment, this guide is written for you.

Multiple myeloma is a cancer of a specific type of white blood cell. For most people it is not considered curable, but the way it is treated has changed dramatically over the past two decades. New drug classes, better supportive care, and refined use of stem cell transplant mean that many people now live for many years with the disease under good control. The experience is often described less as “fighting cancer” in one battle, and more as managing a long-term condition with periods of active treatment, remission, and sometimes relapse.

This article explains what multiple myeloma is, what causes it, how it is diagnosed and staged, the main treatments used today, what to expect during and after a stem cell transplant, how side effects are managed, and what long-term follow-up looks like. It is intended to help you understand the medical landscape so that conversations with your haematologist are easier to follow.

What Is Multiple Myeloma?

Multiple myeloma is a cancer of plasma cells. Plasma cells are a type of white blood cell that lives mainly in the bone marrow, the soft tissue inside bones where blood cells are made. In a healthy body, plasma cells produce antibodies — proteins that help fight infection.

• They crowd out healthy blood-forming cells. This can lead to low red blood cells (anaemia), low white blood cells (more infections), and low platelets (bruising or bleeding).
• They damage bone. Myeloma cells release signals that activate cells which break down bone faster than the body can rebuild it. This can cause bone pain, weak spots called lytic lesions, and fractures.
• They produce an abnormal protein. Myeloma cells make large amounts of one type of antibody, called the monoclonal protein or M-protein. This protein can damage the kidneys and shows up on blood and urine tests.
• They weaken the immune system. Even though there are too many plasma cells, they are all clones of one abnormal cell and cannot fight infection properly. Healthy antibody production drops.

Doctors describe this combination of features using the abbreviation CRAB: high Calcium (from bone breakdown), Renal (kidney) impairment, Anaemia, and Bone disease. These are the classic features that, together with bone marrow findings, define active multiple myeloma.

Types and Related Conditions

Multiple myeloma sits within a family of plasma cell disorders. Understanding where your diagnosis fits can help you make sense of the tests and treatment plan.

Monoclonal Gammopathy of Undetermined Significance (MGUS)

MGUS is a condition in which a small amount of M-protein is found in the blood, but there are no symptoms and no organ damage. MGUS is not cancer. It is, however, a precursor state — a small percentage of people with MGUS go on to develop multiple myeloma over time. People with MGUS are usually monitored with blood tests rather than treated.

Smouldering (Asymptomatic) Multiple Myeloma

Smouldering myeloma is an in-between stage. There are more plasma cells in the bone marrow or more M-protein than in MGUS, but there is still no organ damage. Some people with smouldering myeloma remain stable for years. Others progress to active disease, and certain high-risk features may prompt closer monitoring or earlier treatment in selected cases.

Active (Symptomatic) Multiple Myeloma

This is multiple myeloma that is causing problems — either CRAB features, or specific markers identified by the International Myeloma Working Group (IMWG) that indicate a high likelihood of imminent organ damage. Active myeloma is what most people mean when they say “multiple myeloma,” and it is the stage at which treatment is started.

Solitary Plasmacytoma

Sometimes abnormal plasma cells form a single tumour in a bone or in soft tissue, without spreading widely through the bone marrow. This is called a solitary plasmacytoma. It is often treated with radiation therapy, and people with this diagnosis are watched carefully because some go on to develop multiple myeloma later.

Light Chain and Non-Secretory Myeloma

Most myeloma cells produce a complete M-protein. In some people, the cells only produce part of the antibody (light chains), and in rare cases they produce almost no measurable protein. These variants are tracked using different blood and urine markers but are treated along similar lines.

Causes and Risk Factors

The exact cause of multiple myeloma is not known. What is known is that it begins with genetic changes inside a single plasma cell. These changes are not inherited in most cases — they happen during a person's lifetime.

Factors associated with a higher risk include:

• Age. The risk rises with age. Most people are diagnosed in their 60s or 70s, although younger adults can also develop the disease.
• Sex. Men are diagnosed slightly more often than women.
• Family history. Having a close relative with multiple myeloma or a related plasma cell disorder slightly increases the risk, but most people with myeloma have no affected family member.
• MGUS. Having MGUS is the strongest known risk factor, although the great majority of people with MGUS never progress to myeloma.
• Exposure to certain chemicals and radiation. Long-term exposure to specific industrial chemicals or high doses of radiation has been linked to increased risk in some studies.
• Obesity. Higher body weight has been associated with increased risk in population studies.

It is important to know that multiple myeloma is not contagious, is not caused by anything you ate or did, and is not the result of stress or lifestyle choices. Many people are diagnosed without any identifiable risk factor at all.

Signs and Symptoms

If you have already been diagnosed, you may recognise some of the symptoms that brought you to medical attention. Others reading this may be in the middle of investigations. The most common features of active multiple myeloma include:

• Bone pain, often in the back, ribs, hips, or shoulders. The pain may be persistent, may worsen with movement, and is sometimes mistaken for arthritis or a back problem.
• Fatigue and weakness, often from anaemia.
• Frequent or unusual infections, including chest, sinus, and urinary infections.
• Fractures that happen with little or no obvious injury.
• Kidney problems, sometimes picked up first on a routine blood test showing reduced kidney function.
• Increased thirst, frequent urination, confusion, or constipation, which can be signs of high calcium in the blood.
• Unexplained weight loss.
• Numbness, tingling, or weakness in the legs, which can occur if a myeloma deposit presses on the spinal cord — this is an urgent symptom that needs immediate evaluation.

For those already in treatment, knowing your own pattern of symptoms matters because new or worsening symptoms can be an early sign of relapse. Bone pain in a new location, increasing fatigue, or recurrent infections are worth reporting to your team between scheduled visits.

Diagnosis

Confirming multiple myeloma involves a combination of blood tests, urine tests, imaging, and a bone marrow biopsy. The aim is not only to make the diagnosis but also to measure how much disease is present, whether it is causing organ damage, and what its genetic features are. This information shapes the treatment plan.

Blood Tests

• Complete blood count (CBC) to look for anaemia and other low counts.
• Kidney function and calcium levels.
• Serum protein electrophoresis (SPEP) and immunofixation to detect and identify the M-protein.
• Serum free light chain assay, particularly useful in light chain myeloma.
• Beta-2 microglobulin, albumin, and lactate dehydrogenase (LDH), which help with staging.

Urine Tests

A 24-hour urine collection may be used to measure how much abnormal protein is being filtered through the kidneys.

Bone Marrow Biopsy

A small sample of bone marrow is taken, usually from the back of the hip bone, using a needle under local anaesthetic. The sample is examined to see how many plasma cells are present and to look for genetic abnormalities inside them. The presence of certain chromosomal changes (such as deletions or translocations) helps classify the disease as standard-risk or high-risk, which influences treatment intensity and follow-up.

Imaging

Imaging looks for bone lesions. Whole-body low-dose CT, MRI, and PET-CT are all used in current practice; major guidelines now favour these more sensitive scans over older skeletal X-ray surveys. Imaging is repeated at intervals to monitor bone disease.

Staging and Risk

The Revised International Staging System (R-ISS) is the framework most widely used to stage multiple myeloma. It combines blood markers (albumin, beta-2 microglobulin, LDH) with the genetic findings from the bone marrow to place the disease into stage I, II, or III. Staging gives a general sense of how the disease is likely to behave but does not by itself decide treatment.

Treatment and Management

Treatment for multiple myeloma is built around combinations of drugs, given in cycles, often followed by an autologous stem cell transplant in people who are fit enough, and then a long phase of maintenance therapy. Choices are personalised based on age, fitness, kidney function, genetic risk, and personal preferences. Major guidelines from the International Myeloma Working Group, NCCN, and ESMO describe several effective combinations; the specific regimen your haematologist recommends depends on these factors and on availability.

The Main Drug Classes

Modern myeloma treatment uses drugs from several categories, usually in combination:

• Proteasome inhibitors (for example bortezomib, carfilzomib, ixazomib) interfere with how myeloma cells dispose of waste proteins, causing the cells to die.
• Immunomodulatory drugs (IMiDs) (such as lenalidomide, pomalidomide, and thalidomide) change the environment around myeloma cells and activate the immune system against them.
• Monoclonal antibodies (such as daratumumab and isatuximab, which target a protein called CD38 on myeloma cells; and elotuzumab) attach to myeloma cells and mark them for destruction by the immune system.
• Steroids (commonly dexamethasone) have a direct anti-myeloma effect and are part of most regimens.
• Traditional chemotherapy (for example cyclophosphamide or melphalan) is still used in some combinations and as part of stem cell transplant.

Newer Immunotherapies for Relapsed Disease

Several newer approaches are reshaping treatment of myeloma that has come back after earlier therapies:

• CAR-T cell therapy, in which a patient's own immune cells are collected, modified in a laboratory to recognise myeloma cells, and infused back. It is currently used mostly for relapsed or refractory disease.
• Bispecific antibodies, which act as a bridge connecting an immune cell to a myeloma cell so that the immune system can destroy it. Several have been approved for later lines of therapy.
• Antibody-drug conjugates, which combine an antibody with a chemotherapy payload that is delivered directly to myeloma cells.

These therapies have moved several previously untreatable situations into the realm of meaningful response. Eligibility, sequencing, and access vary, and the appropriate moment to use them is a clinical judgement.

Radiation Therapy

Radiation is used in specific situations rather than as a primary myeloma treatment. It can relieve severe localised bone pain, treat solitary plasmacytomas, or be used urgently when a myeloma deposit is pressing on the spinal cord.

Supportive Care

Supportive care is just as important as anti-myeloma drugs and runs alongside them throughout treatment:

• Bone-strengthening medicines (bisphosphonates such as zoledronic acid, or denosumab) reduce the risk of fractures and bone pain.
• Infection prevention, including vaccinations (e.g., influenza, pneumococcal, COVID-19, shingles where appropriate), preventive antibiotics or antivirals during specific treatment phases, and sometimes intravenous immunoglobulin in people with frequent infections.
• Blood transfusions or erythropoiesis-stimulating agents for severe anaemia.
• Kidney protection through good hydration, careful drug dosing, and avoidance of medications that strain the kidneys.
• Pain management using a stepped approach that may include physiotherapy, nerve pain medications, and procedures such as vertebroplasty or kyphoplasty for collapsed vertebrae.
• Blood clot prevention, since some myeloma drugs increase clotting risk and blood thinners may be advised.

Autologous Stem Cell Transplant

For people who are fit enough, an autologous stem cell transplant is a standard part of first-line treatment. “Autologous” means using your own stem cells. The aim is to deliver a high dose of chemotherapy that would otherwise be too damaging to the bone marrow, and then rescue the bone marrow by giving back stem cells that were collected and stored earlier.

Who Is Considered for Transplant

Eligibility is based on overall fitness rather than a strict age cut-off. Heart, lung, and kidney function, other medical conditions, and the response to initial drug therapy are all considered. Many people in their late 60s and 70s undergo transplant successfully. People who are not fit for transplant continue on drug-based therapy without it — modern combination regimens produce strong results in this group as well.

How the Process Unfolds

1. Induction therapy. Several months of combination drug therapy to reduce the amount of myeloma before transplant.
2. Stem cell mobilisation and collection. Medications are used to push stem cells out of the bone marrow and into the bloodstream, where they are collected through a process similar to blood donation (apheresis) over one or more sessions.
3. Conditioning chemotherapy. A high dose of melphalan is given to wipe out remaining myeloma cells in the bone marrow.
4. Stem cell infusion. The stored stem cells are returned through a drip. They find their way back to the bone marrow and start producing new blood cells over the following two to three weeks.
5. Engraftment and recovery. Blood counts are very low for a period of about two to three weeks. This is usually managed in hospital or in a closely monitored day-care setting, with attention to infection risk, nutrition, and transfusions as needed.

Recovery to normal energy levels typically takes several months. Stem cell transplant is not a cure, but it commonly produces a deeper and longer-lasting remission than drug therapy alone. After transplant, most people continue on maintenance therapy — usually a lower-intensity oral medication taken long-term — to keep the disease suppressed.

Allogeneic Transplant

Allogeneic transplant uses stem cells from a donor. It carries higher risks and is used selectively in myeloma, mainly in younger patients with aggressive or relapsed disease, and within carefully chosen contexts.

What Treatment Feels Like Day to Day

Drug treatment for myeloma is given in cycles, typically lasting three or four weeks. Within each cycle, some medications are given as infusions or injections, others as tablets at home. A cycle includes treatment days and rest days. Many people continue working part-time or managing daily life around their treatment schedule, particularly once side effects are familiar and well controlled.

Typical aspects of life during active treatment include regular clinic visits, blood tests before each cycle, periodic imaging, and ongoing supportive medications. Around stem cell transplant, life narrows for a few weeks to focus on safety, infection prevention, and recovery. After that, the rhythm gradually opens up again.

Side Effects and How They Are Managed

Side effects depend on which drugs are used, how long treatment continues, and individual factors. Most are manageable with dose adjustments and supportive medicines. Common ones include:

• Fatigue. Often the most persistent symptom. Pacing, light exercise, and addressing anaemia all help.
• Peripheral neuropathy. Tingling, numbness, or burning in the hands and feet, particularly from bortezomib and thalidomide. Reporting it early allows the dose or schedule to be adjusted before it becomes severe.
• Increased infection risk. Especially during steroid-containing cycles, after transplant, and with newer immunotherapies.
• Blood clots. Particularly with IMiDs combined with steroids. Preventive blood thinners are often used.
• Gastrointestinal effects. Nausea, constipation, or diarrhoea, depending on the regimen.
• Mood and sleep changes from steroids.
• Skin reactions and injection site discomfort.
• Changes in blood counts, requiring transfusions or growth-factor injections in some cases.
• Infusion reactions with monoclonal antibodies, usually during the first dose and managed with pre-medication.

Some side effects specific to newer immunotherapies, including cytokine release syndrome and neurological effects with CAR-T cell therapy and bispecific antibodies, are well recognised and managed by teams experienced with these treatments. They require monitoring in a specialised setting for a defined period after the therapy is given.

Monitoring and Response

Doctors use response categories defined by the International Myeloma Working Group, ranging from stringent complete response (no detectable disease by available tests) through very good partial response, partial response, and stable disease. A newer measure, minimal residual disease (MRD), uses highly sensitive bone marrow tests to detect very small numbers of myeloma cells that remain after treatment. Deeper responses, including MRD negativity, are associated with longer remission, although the role of MRD in guiding treatment decisions is still being defined.

Typical monitoring during maintenance includes blood tests every one to three months, periodic bone marrow biopsies when needed, and imaging when symptoms or markers suggest a change.

Living With Multiple Myeloma

Multiple myeloma is usually framed as a long-term condition rather than a single event. People often move through phases of intensive treatment, recovery, remission, and sometimes relapse, with treatment shifting at each stage. Adapting to this rhythm is one of the practical tasks of living with the disease.

Physical Activity

Staying active, within the limits of bone health and energy, helps with fatigue, mood, and overall fitness. Walking, gentle resistance work, and supervised physiotherapy are commonly recommended. High-impact activities and movements that load the spine heavily are usually avoided if there is significant bone disease — your team can advise on what is safe.

Nutrition and Hydration

A balanced diet that supports muscle and bone, adequate fluid intake to protect the kidneys, and attention to vitamin D and calcium status are common areas of focus. Specific dietary restrictions, including precautions around food safety, may apply during periods of low immunity such as after transplant.

Infection Awareness

Because the immune system is affected both by myeloma and by its treatment, infection prevention is an ongoing theme — hand hygiene, avoiding sick contacts during high-risk periods, keeping vaccinations current, and reporting fever or new symptoms promptly. Your team will give you a clear plan for when to call.

Emotional and Psychological Support

Living with a long-term cancer is demanding. Anxiety around scans and blood test results (sometimes called “scanxiety”), worry about relapse, body image changes, and the strain on family relationships are all common. Counselling, peer support groups, and psycho-oncology services are part of comprehensive care. Family members and carers also benefit from support.

Sexual Health and Fertility

Some myeloma treatments affect fertility. People of childbearing age are usually offered a discussion about fertility preservation before treatment that may affect this, where time allows. Sexual health concerns, including effects of fatigue, neuropathy, hormonal changes, and emotional impact, can be discussed openly with the treating team.

Work and Daily Roles

Many people continue some form of work during treatment, particularly during maintenance phases. Flexibility, fatigue management, and infection precautions usually shape the arrangement more than the diagnosis itself.

Complications to Be Aware Of

Even with treatment, multiple myeloma can cause complications that need active management:

• Bone fractures and spinal cord compression. Sudden severe back pain, new weakness in the legs, or problems with bladder or bowel control require urgent assessment.
• Kidney injury. May develop gradually or suddenly. Regular monitoring and avoidance of certain medications help reduce the risk.
• High calcium in the blood. Can cause confusion, severe thirst, constipation, or kidney problems and needs prompt treatment.
• Severe infections. Fever, chills, or breathlessness during treatment are reasons to contact the team without delay.
• Hyperviscosity. In a minority of patients, very high levels of M-protein make the blood thicker than normal and may cause headaches, blurred vision, or bleeding from the nose or gums. This requires specific treatment.
• Second cancers. Long-term treatment slightly raises the risk of certain secondary cancers, which is one reason for ongoing follow-up.

When to Seek Urgent Care

While in active treatment or follow-up, contact your team or seek urgent medical attention for:

• Fever (commonly defined as 38°C / 100.4°F or above) or shaking chills
• New, severe, or rapidly worsening bone pain
• New weakness, numbness, or loss of control of bladder or bowels
• Severe headache, confusion, or sudden visual changes
• Breathlessness, chest pain, or new swelling in a leg
• Heavy bleeding or extensive new bruising
• Significant decrease in urination or sudden swelling

Your team will usually give you a written plan and contact numbers tailored to your treatment phase.

Multiple Myeloma in Younger Adults and Children

Multiple myeloma is overwhelmingly a disease of older adults; the median age at diagnosis is in the mid-60s. It is rare under 40 and extremely rare in children. When it does occur in younger adults, treatment principles are similar, but more aggressive strategies (including transplant) and longer durations of maintenance may be considered because of the long horizon ahead. Fertility counselling becomes especially important.

For paediatric and adolescent patients, plasma cell disorders are uncommon enough that care is typically directed through specialised paediatric haematology-oncology centres with experience in rare cancers.

Long-Term Outlook

The outlook in multiple myeloma has improved substantially over the last two decades. Many people now live for years with the disease under control, and a meaningful proportion live a decade or longer, particularly with standard-risk disease and a good response to first-line treatment. Outcomes vary widely depending on age, genetic risk features, kidney function at diagnosis, response to therapy, and access to newer treatments.

Rather than a single survival figure, it is more useful to think in terms of lines of therapy: a first treatment plan, often including transplant, brings the first remission; when the disease relapses, a second-line plan takes over, and so on. With each new drug class that has entered practice, the number of effective lines available has grown. Conversations with your haematologist about your own expected course will be more accurate than any general number, because they take your specific disease features into account.

Preventing Progression and Complications

Multiple myeloma itself cannot be prevented. What can be influenced is how well the disease and its treatment are managed:

• Sticking to the treatment and monitoring schedule, including maintenance therapy
• Keeping appointments for blood tests and imaging
• Reporting new symptoms early rather than waiting for the next scheduled visit
• Maintaining bone-strengthening treatment and vitamin D as advised
• Keeping up with vaccinations
• Managing other health conditions, such as blood pressure, diabetes, and heart disease, since these affect overall fitness for treatment
• Avoiding smoking and limiting alcohol
• Staying physically active within safe limits

For people with MGUS or smouldering myeloma, regular monitoring is the main intervention. Most people in these categories never need treatment, but monitoring catches progression early when it does occur.

Frequently Asked Questions

Is multiple myeloma curable?

For most people, multiple myeloma is not considered curable, but it is highly treatable. Many people achieve deep remissions that last years, and treatment continues to improve. A small number of people, particularly those with deep responses including MRD negativity sustained for many years, may have outcomes that resemble a functional cure, although the disease can return after long intervals.

Will I need a stem cell transplant?

Not everyone needs a transplant. Eligibility depends on overall fitness, response to initial treatment, and personal preference. People who are not transplant candidates can do well on drug-based regimens alone. Whether to pursue transplant, and when, is one of the main decisions to discuss with your haematologist after the first few cycles of induction therapy.

How long does treatment last?

Initial intensive treatment typically lasts several months. If a transplant is part of the plan, that adds further time. After this, most people continue on maintenance therapy — usually a lower-intensity oral medication — for an extended period, often for years. In this sense, treatment is ongoing rather than time-limited.

Can I work and travel during treatment?

Many people manage some level of work and travel between cycles. Activity is usually most restricted during induction, around stem cell transplant, and during any acute side effects. Maintenance therapy is often compatible with a near-normal routine. Air travel, infection precautions, and timing of vaccinations are worth planning with your team.

Is multiple myeloma inherited? Should my family be tested?

Most cases are not inherited. There is a small increase in risk for close relatives, but routine testing of family members is not generally advised. If there is a strong family history of plasma cell disorders, this can be discussed with the haematology team.

What is the difference between MGUS, smouldering myeloma, and multiple myeloma?

MGUS and smouldering myeloma are precursor conditions without organ damage; they are monitored, not treated, in most cases. Active multiple myeloma is the stage at which treatment begins, defined by either organ damage (CRAB features) or specific high-risk markers.

What does relapse mean, and what happens then?

Relapse means the disease has come back after a period of control. It is often picked up on blood tests before symptoms return. Many effective treatment options exist for relapsed disease, and a new treatment plan is built based on which drugs were used before, how long the remission lasted, and your overall health. Relapse is a turning point in the journey rather than an end of options.

Can I have vaccinations during treatment?

Most non-live vaccines are encouraged, often timed around treatment cycles for the best immune response. Live vaccines are generally avoided during active treatment. Your team will guide which vaccines to have and when, particularly after transplant when a vaccination programme is usually restarted.

How often will I need follow-up?

During active treatment, visits are frequent — often every few weeks. During maintenance and remission, visits typically space out to every one to three months, with periodic imaging. Frequency increases again if there are concerns about relapse or new symptoms.

Conclusion

Multiple myeloma is a complex blood cancer, but the picture today is very different from what it was even fifteen years ago. New drug classes, refined use of stem cell transplant, immunotherapies such as CAR-T cell therapy and bispecific antibodies, and better supportive care have shifted myeloma into the category of long-term, manageable cancers for many people. Treatment unfolds over years, with active phases, remissions, and adjustments at each step.

Understanding the language of the disease — M-protein, CRAB, induction, transplant, maintenance, response, relapse — makes it easier to follow conversations with your haematology team and to take part in decisions. With clear information, structured follow-up, and a treatment plan built around your specific disease and health, it is possible to live well alongside multiple myeloma for a long time.